Cellectis to present at BioCapital Europe Amsterdam and Bio Chicago, two major Biotech events

Printer-friendly versionPDF version

Cellectis (Alternext: ALCLS), the French genome engineering specialist, will participate in the following Biotech events:

Paris, April 22, 2010 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, will participate in the following Biotech events:

* BioCapital Europe, April 29, 2010, in Amsterdam, the Netherlands: André Choulika, Cellectis’ CEO, will present the company to Biotech VCs and institutional investors at 4:20PM in room 1, at the Krasnapolsky Hotel, in Amsterdam.

* Bio International Convention, May 3-6, 2010, in Chicago, USA: Dirk Pollet, Cellectis’ Chief Business Officer will take part in the panel “Effective Academia and Industry Interactions: The Role of Patents in Attracting Industry Interest in This Economy”, to be held on May 6, 2010, at 8:00AM, in room N427A at the McCormick Place in Chicago.

Cellectis SA is a world leader in genome engineering. The company specializes in the development and production of meganucleases (DNA scissors) for in vivo genome surgery. Cellectis products are programmed to induce unique, site-directed, double-strand DNA breaks in a living cell and can be used for a wide range of therapeutic and biotechnological applications.

News Source : Cellectis to present at BioCapital Europe Amsterdam and Bio Chicago, two major Biotech events